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Summary
 
Limitation of clonal expansion of activated T cells is necessary for immune homeostasis, and is
achieved by growth arrest and apoptosis. Growth arrest and apoptosis can occur passively sec-
ondary to cytokine withdrawal, or can be actively induced by religation of the T cell receptor
(TCR) in previously activated proliferating T cells. TCR-induced apoptosis appears to require
prior growth arrest, and is mediated by death receptors such as Fas. We tested whether TCR
religation affects T cell responses to interleukin (IL)-2, a major T cell growth and survival fac-
tor. TCR ligation in activated primary human T cells blocked IL-2 induction of signal trans-
ducer and activator of transcription (STAT)5 DNA binding, phosphorylation of STAT5, Janus
kinase (Jak)1, Jak3, and Akt, and kinase activity of Jak1 and Jak3. Inhibition was mediated by
the mitogen-activated protein kinase kinase (MEK)–extracellular stimulus–regulated kinase (ERK)
signaling pathway, similar to the mechanism of inhibition of IL-6 signaling we have described
previously. TCR ligation blocked IL-2 activation of genes and cell cycle regulatory proteins,
and suppressed cell proliferation and expansion. These results identify TCR-induced inhibition
of IL-2 signaling as a novel mechanism that underlies antigen-mediated feedback limitation of
T cell expansion, and suggest that modulation of cytokine activity by antigen receptor signals plays
an important role in the regulation of lymphocyte function.
Key words: cytokines • signal transduction • inhibition • mitogen-activated protein kinases • 
gene activation
 
U
 
ncontrolled exuberance of an immune response leads to
direct toxicity to the host and may predispose to autoim-
munity. Prominent examples include mortality in human pa-
tients unable to limit responses to superantigens produced by
 
Staphylococcus aureus
 
 (1), in mice that are unable to restrain
CD4
 
1
 
 T cell responses to lymphocytic choriomeningitis virus
(2), and autoimmune syndromes in mice and humans (for a
review, see reference 3). Several mechanisms of limiting T cell
responses have been described. Negative signaling by mol-
ecules such as CTL-associated molecule 4 (CTLA4), and by
cytokines such as IL-10 and TGF-
 
b
 
, can suppress T cell pro-
liferation (3). Growth arrest and apoptosis secondary to low
levels of proliferative or antiapoptotic cytokines such as IL-2
and type I IFNs have been implicated in the limitation and
termination of responses to several pathogens and antigens, in-
cluding viruses and 
 
Staphylococcus
 
 enterotoxins A (SEA)
 
1
 
 and
SEB (3–7). Apparently paradoxical feedback inhibition by
recurrent stimulation with the antigen that initiated the re-
sponse is an important mechanism of restraining ongoing T
cell responses (3). TCR-induced feedback inhibition oc-
curs by a combination of growth arrest (2, 8–13) and in-
duced apoptotic cell death (14), which appear to be linked,
as growth arrest precedes, and may be required for, apopto-
sis (15). Antigen-mediated feedback inhibition is especially
effective when persistent or high-affinity antigens interact
with TCRs on activated and rapidly cycling cells (16).
TCR-induced apoptosis is mediated by specific death re-
ceptors such as Fas and TNF receptor 1, and by modulation
of signaling by these receptors (14, 17–21). TCR-induced
 
1
 
Abbreviations used in this paper:
 
 CCR2, CC chemokine receptor 2; cdk,
cyclin-dependent kinase; CIS, cytokine-inducible SH2 protein; EMSA,
electrophoretic mobility shift assay; ERK, extracellular stimulus–regulated
kinase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; GAS, gamma-
activated sequence; GRR, gamma response region; IRF, IFN regulatory
factor; Jak, Janus kinase; MAPK, mitogen-activated protein kinase; MEK,
MAPK kinase; MNC, mononuclear cell; PKC, protein kinase C; Rb, retino-
blastoma protein; RT, reverse transcription; SEA, 
 
Staphylococcus
 
 entero-
toxin A; SOCS, suppressor of cytokine signaling; STAT, signal transducer
and activator of transcription. 
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growth arrest in T cell hybridomas and lines that do not
regulate growth in a normal, physiological fashion has been
linked to downregulation of cell cycle regulatory proteins
such as cyclin D3 and cyclin-dependent kinase 2 (cdk2) (10,
15). Mechanisms underlying TCR-induced growth arrest
of primary T cells, which are dependent on growth factors
and cytokines for proliferation and survival (5–7, 22), are
not known. We considered the hypothesis that TCR liga-
tion in cycling cytokine-dependent T cells may block cy-
tokine activity by inhibiting signal transduction. Such inhi-
bition of signaling would limit T cell responses by several
mechanisms, including growth arrest and apoptosis second-
ary to decreased survival signals, and would sensitize cells
for apoptosis mediated by death receptors, which appears to
depend on prior growth arrest (15, 23).
One important component of TCR signaling is the activa-
tion of a kinase cascade involving protein kinase C (PKC)
 
®
 
Raf
 
®
 
mitogen-activated protein kinase kinase (MEK)1,
MEK2
 
®
 
extracellular stimulus–regulated kinase (ERK)1,
ERK2 (24). The ERKs constitute one family of mitogen-
activated protein kinases (MAPKs) that are downstream ef-
fector kinases in a signaling pathway activated by a large
number of extracellular ligands. Interestingly, cellular pro-
liferative responses to ERKs are highly dependent on cell
type and activation status, and ERKs can induce either pro-
liferation or growth arrest and senescence (25–27). Fur-
thermore, we have previously shown that activation of
the MEK-ERK pathway blocks signaling and activation of
signal transducer and activator of transcription (STAT)3 by
IL-6 (28, 29), and a PKC-dependent pathway has been shown
to enhance susceptibility to Fas-mediated apoptosis (30).
Therefore, we tested whether activation of the MEK-ERK
pathway by religation of the TCR in previously activated
T cells inhibits IL-2 signaling, thus inducing a functional
withdrawal of cells from the effects of IL-2. Activation of
IL-2 signaling pathways and target genes was inhibited by
TCR ligation, and inhibition of signaling correlated with
decreased proliferation and subsequent cell death. These
results demonstrate that cross-talk between two major sig-
naling pathways in T cells has important functional conse-
quences for modulating the extent of cell expansion.
 
Materials and Methods
 
Cell Culture.
 
Mononuclear cells (MNCs) were obtained from
whole blood from disease-free volunteers by density gradient
centrifugation using Ficoll metrizoate (Lymphoprep; GIBCO BRL).
MNCs were depleted of CD56
 
1
 
 NK cells using the MACS sepa-
ration system (Miltenyi Biotec) and CD56-specific, paramagnetic
beads. In pilot experiments, CD8
 
1
 
 or CD4
 
1
 
 cells were also de-
pleted, and in all cases depletion was verified using flow cytometry
(see below). In experiments with superantigens, cells were acti-
vated with SEA (Sigma Chemical Co.) in complete media (CM)
containing RPMI (GIBCO BRL) supplemented with 10% fetal
bovine serum (Hyclone) and 2 mM 
 
l
 
-glutamine for 3 d, and
SEA-reactive T cells were expanded in IL-2 and added to adher-
ence-purified monocytes. Otherwise, purified OKT3 antibody
(Coulter) was added to NK cell–depleted MNCs at a 1:1,000
dilution that strongly activated T cells in initial titration experi-
ments, and cells were harvested after 3 d, washed, and used for
experiments or expanded in IL-2 as noted in the figure legends.
An aliquot was saved for flow cytometric analysis of cell surface
phenotype, and remaining cells (
 
.
 
90% CD3
 
1
 
) were plated in
wells that had been coated with 10 
 
m
 
g/ml of rabbit anti–mouse
Ig and 3 
 
m
 
g/ml of either anti-CD3 (clone UCHT-1; PharMingen)
or an isotype-matched irrelevant control antibody. Initial dose–
response experiments demonstrated that the effects of anti-CD3
saturated at 1–2 
 
m
 
g/ml. Additional anti-CD3 antibodies that were
used with similar results were 4B5 (Boehringer Mannheim) and
HIT3a (Immunotech), and anti-CD4 antibodies (RPA-T4; Phar-
Mingen) were also used as an additional control.
 
Flow Cytometry.
 
Cells were analyzed using flow cytometry as
described previously (31) using the following antibodies: T cell and
activation markers, UCHT-1 and 4B5 (anti-CD3), RPA-T4 (anti-
CD4), HIT8a (anti-CD8), M-A251 (anti-CD25), CF1 and Mik-
 
b
 
3
(anti-CD122), AG184 (anti-
 
g
 
c
 
); NK cell marker, 3G8 (anti-CD16);
monocyte marker, IV.3 (anti-CD32 monocyte-specific epitope);
and 48607 (anti–CC chemokine receptor 2 [CCR2]). AG184,
M-A251, HIT8a, and Mik-
 
b
 
3 were obtained from PharMingen,
4B5 and 3G8 from Boehringer Mannheim, CF1 from Immuno-
tech, IV.3 from Medarex, and 48607 from R&D Systems. Analyses
were done using a FACScan™ flow cytometer with CELLQuest
software™ (Becton Dickinson).
 
Cell Lysis, Electrophoretic Mobility Shift Assay, Immunoprecipitation,
and Immunoblotting.
 
Cell extracts were obtained as described pre-
viously (29). Extracts corresponding to 3.3 
 
3
 
 10
 
5
 
 cells (
 
z
 
12 
 
m
 
g
of protein) were incubated for 15 min at room temperature with
0.5 ng of 
 
32
 
P-labeled double stranded oligonucleotide containing
the gamma-activated sequence (GAS) STAT-binding site from the
IFN regulatory factor (IRF) promoter in a 15-
 
m
 
l binding reaction
containing 40 mM NaCl and 2 
 
m
 
g of poly-dI-dC (Amersham
Pharmacia Biotech), as described previously (29), and complexes
were resolved on nondenaturing 4.5% polyacrylamide gels. For
immunoblotting, cell lysates were fractionated on 7.5 or 10% poly-
acrylamide gels using SDS-PAGE, transferred to polyvinylidene
fluoride membranes (Millipore), and incubated with specific anti-
bodies, and enhanced chemiluminescence was used for detection.
mAbs against Janus kinase (Jak)1 (clone 73) and STAT5 (clone
89) were obtained from Transduction Laboratories, anti-cyclin
D3 (D-7) from Santa Cruz Biotechnology, anti-underphosphory-
lated retinoblastoma protein (Rb, G99-549) from PharMingen,
and antiphosphotyrosine (4G10) and anti-tyrosine phosphory-
lated STAT5 from Upstate Biotechnology. Polyclonal antibodies
against Jak1 (Q-19), STAT5 (C-17), and cyclin D3 (C-16) were
from Santa Cruz Biotechnology, and anti-tyrosine phosphorylated
Jak1 was from Quality Control Biochemicals. In most cases, results
were confirmed using two different antibodies. Immunoprecipi-
tations were performed by adjusting cell extracts obtained from
20 
 
3
 
 10
 
6
 
 cells to a volume of 0.5 ml and incubating with 2–4 
 
m
 
g
of specific antibody for 4 h at 4
 
8
 
C. Immunoprecipitates were
collected using protein A and protein G agarose beads (Pierce
Chemical Co.), washed twice in lysis buffer and once in PBS, re-
solved by SDS-PAGE, and analyzed by immunoblotting.
 
In Vitro Kinase Assays.
 
Jak1 and Jak3 immunoprecipitates were
obtained from 40 
 
3
 
 10
 
6
 
 cells that had been lysed in buffer con-
taining 0.5% NP-40, 10% glycerol, 50 mM Tris-HCl (pH 8.0),
200 mM NaCl, 0.1 mM EDTA, 1 mM dithiothreitol, 1 mM
Na
 
3
 
VO
 
4
 
, and protease inhibitors, as described previously (29), using
Jak1 (Q-19) or Jak3 antibodies (provided by J. O’Shea, National In-
stitutes of Health, Bethesda, MD). After washes in lysis buffer and ki-
nase buffer containing 20 mM Hepes (pH 7.4), 50 mM NaCl, 5 mM
MgCl
 
2
 
, 5 mM MnCl
 
2
 
, and 0.1 mM Na
 
3
 
VO
 
4
 
, 25% of immunopre- 
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cipitates were saved for immunoblotting, and the remainder was in-
cubated for 30 min at room temperature in 40 
 
m
 
l of kinase buffer
with 1 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP. 1 
 
m
 
M unlabeled ATP was added to Jak3
kinase reactions. 
 
32
 
P-labeled proteins were washed in kinase buffer
and PBS, and analyzed using SDS-PAGE and autoradiography.
 
Transfections and Reporter Gene Assays.
 
Kit225 cells, a human
IL-2–dependent cell line (32), were maintained in CM containing
20 U/ml of IL-2, and deprived of IL-2 for 24 h before transfection.
10
 
7
 
 cells were transfected using electroporation and the Bio-Rad
Gene Pulser (320 V, 960 
 
m
 
F) with 20 
 
m
 
g of total DNA (10 
 
m
 
g of
5
 
3
 
 gamma response region [GRR] GAS-luciferase reporter [32]),
2 
 
m
 
g of lacZ encoding plasmid, and 8 
 
m
 
g of empty control vector
or vector encoding constitutively active MEK1 (containing the
S218E, S222D mutations and an NH
 
2
 
-terminal deletion of residues
30–49) or kinase-inactive MEK1 (29). Cells were stimulated with
100 U/ml of IL-2 for 6 h, and luciferase activity was measured as
described previously (29), and normalized for 
 
b
 
-galactosidase activ-
ity encoded by the cotransfected control plasmid.
 
Analysis of mRNA Levels.
 
Total cellular RNA was isolated
using Trizol (GIBCO BRL) according to the instructions of the
manufacturer. For reverse transcription (RT)-PCR, RNA was
treated with RNase-free DNase, and cDNA was obtained using
Moloney murine leukemia virus reverse transcriptase (GIBCO
BRL). 2.5% of each cDNA was subjected to 25 cycles of PCR
using conditions that result in a single specific amplification prod-
uct of the correct size as described previously (33): 30 s denatur-
ation at 94
 
8
 
C, 1 min annealing at 55
 
8
 
C, and 30 s extension at 72
 
8
 
C
in a GeneAmp 9600 thermal cycler (Perkin-Elmer Corp.). dNTPs
were used at 100 
 
m
 
M, and 1 
 
m
 
Ci of [
 
a
 
-
 
32
 
P]dATP was added to
each reaction. No amplification products were obtained when re-
verse transcriptase was omitted, indicating the absence of con-
taminating genomic DNA. Amplification was empirically deter-
mined to be in the linear range. Oligonucleotide primers for the
cytokine-inducible SH2 protein (CIS) and PGE2R genes were
provided by C. Beadling and K. Smith (Weill Medical College of
Cornell University [34]), and additional primer sequences are Fos:
CCG AGA TTG CCA ACC TGC TGA A and CAC TGG
GCC TGG ATG ATG C; suppressor of cytokine signaling
(SOCS)1 (three sets): GGA CGC CTG CGG ATT CTA CTG G
and TCG CGG AGG ACG GGG TTG AG, CGA CGG CGG
CCA GAA CCT TC and GTG AAA GCG GCC GGC CTG
AAA GT, and CTC CGG CTG GCC CCT TCT GTA G and
TGA AAG CGG CCG GCC TGA AAG TG; SOCS3: CAC
TAC ATG CCG CCC CCT GGA G and TCG CCC CCG
GAG TAG ATG TAA T; and glyceraldehyde 3-phosphate dehy-
drogenase (GAPDH): GTG AAG GTC GGA GTC AAC and
TGG AAT TTG CCA TGG GTG.
 
Proliferation Analysis.
 
10
 
5
 
 cells in 100 
 
m
 
l of medium were seeded
in triplicate in 96-well tissue culture plates that had been coated
with 10 
 
m
 
g/ml of rabbit anti–mouse Ig and 3 
 
m
 
g/ml of anti-CD3 or
control antibody. Cells were pulsed for 4 h with 10 
 
m
 
Ci/ml of
[
 
3
 
H]thymidine and harvested using an automated cell harvester
(Harvester 96; Tomtec), and [
 
3
 
H]thymidine incorporation was
quantitated using a Microbeta Trilux Scintillation Counter (Wal-
lac). Cell counts were performed in duplicate, and cell viability was
determined using trypan blue and propidium iodide exclusion.
 
Results
 
TCR Ligation Blocks Activation of STAT5 by IL-2.
 
IL-2
is a major growth factor for activated T cells and plays an
important role in lymphocyte expansion and differentiation
during an immune response (for reviews, see references
35–38). Activation of STAT5 is an important component
of IL-2 signaling (38), and the effect of TCR cross-linking
on IL-2 induction of STAT5 DNA binding activity was an-
alyzed. Since staphylococcal superantigens are high-affinity
naturally occurring TCR ligands that initially lead to vigor-
ous immune responses, which subsequently are strongly lim-
ited (1), the effect of SEA on IL-2 signaling was determined.
Freshly isolated MNCs from normal donors were depleted
of NK cells, activated with SEA, and SEA-reactive T cells
were expanded in IL-2. T cells were then added to tissue
culture wells containing APCs in the presence or absence
of SEA for 1 h, stimulated with IL-2 for 10 min, and cell
extracts were assayed for STAT DNA-binding activity by
electrophoretic mobility shift assays (EMSAs; Fig. 1 A).
Treatment with IL-2 resulted in the rapid induction of a
DNA–protein complex (lane 3) that bound the IRF GAS
oligonucleotide specifically and corresponded to STAT5
(33; and data not shown), and treatment with SEA resulted
in significant inhibition of IL-2 activation of STAT5 DNA
binding activity (lane 4); similar results were obtained with
SEB (data not shown). Immunoblotting demonstrated com-
parable levels of STAT5 in all extracts (Fig. 1 A, lower
panel), indicating that SEA treatment suppressed activation
of DNA binding and did not decrease STAT5 protein levels.
To determine whether APCs or APC products were
required for inhibition, TCRs were cross-linked using plate-
bound anti-CD3 antibodies in the absence of APCs. Acti-
vation of STAT5 DNA binding was suppressed by TCR li-
gation (Fig. 1 B). Suppression of STAT5 activation by TCR
ligation (40–90% inhibition relative to control) was consis-
tently detected in 
 
.
 
40 independent experiments using dif-
ferent blood donors, and was observed with a broad range
of IL-2 doses (between 2 and 100 U/ml), with cross-link-
ing times of 0.5–4 h, with purified CD4
 
1
 
 or CD8
 
1
 
 cells,
and with several antibodies that ligate the TCR, but not
with irrelevant or anti-CD4 antibodies (data not shown).
Consistent with previous reports that TCR signaling is less
dependent on costimulation in activated T cells (39), co-
cross-linking of CD28 had no additional effect, but phar-
macological mimicking of maximal TCR stimulation using
PMA plus ionomycin more strongly inhibited STAT5 acti-
vation (data not shown).
Figure 1. TCR ligation blocks
IL-2 activation of STAT5 DNA
binding. Preactivated T cells
(.90% CD31) were added to
wells containing purified mono-
cytes, and SEA (2 mg/ml) was
added (A); or to wells coated with
isotype-matched control or anti-
CD3 antibodies (B), for 1 h, fol-
lowed by a 10-min stimulation
with IL-2 (100 U/ml). Cell ex-
tracts were analyzed using EMSA
with the IRF oligonucleotide and
immunoblotting (IB) as described
previously (reference 33). 
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Tyrosine phosphorylation of STAT5 is required for DNA
binding (38), and the effect of SEA or TCR cross-linking
on IL-2–induced tyrosine phosphorylation was examined.
IL-2–induced tyrosine phosphorylation of STAT5 was sup-
pressed by SEA treatment (Fig. 2 A, lanes 3 and 4) or TCR
cross-linking (Fig. 2 B, lanes 2 and 4). Immunoblotting
demonstrated comparable levels of STAT5 in all extracts
(Fig. 2). Rapid and transient activation of STAT5 tyrosine
phosphorylation, which has been reported by one group
after TCR cross-linking (detected after 7 min, and absent
after 15 min [40]), was not detected in the time frame of
these experiments. The results showing inhibition of STAT5
tyrosine phosphorylation confirm the DNA binding results
(Fig. 1), and suggest that TCR ligation blocks STAT5 acti-
vation. The mechanism of inhibition of IL-2 signaling by
TCR cross-linking was further explored using the more
simple system with plate-bound antibodies, which elimi-
nated potential contributions from APCs or ligation of ad-
ditional T cell surface proteins.
 
Inhibition of IL-2 Signaling Occurs Upstream of STAT5
Activation, and Akt Activation is Also Blocked.
 
Activation of
STAT5 by IL-2 depends on membrane-proximal events
including the phosphorylation and activation of Jak1 and
Jak3 kinases (38). IL-2–induced tyrosine phosphorylation of
Jak1 and Jak3 was suppressed by TCR cross-linking (Fig. 3,
A and B), and Jak kinase activity was suppressed in parallel
(Fig. 3, A and B). Similar results were obtained using an
antibody specific for tyrosine-phosphorylated Jak1 (data not
shown). These results indicate that TCR cross-linking sup-
pressed the activation of IL-2 signaling upstream of STAT5
activation, and suggest that additional IL-2 signaling path-
ways downstream of the Jaks may be affected. Activation of
the Akt kinase (also termed protein kinase B) by IL-2 is im-
portant for proliferation and suppression of apoptosis (32, 41),
and the effect of TCR cross-linking on activation of Akt
was investigated using immunoblotting with antibodies
specific for the activated, phosphorylated form of Akt (Fig.
3 C). TCR cross-linking effectively suppressed IL-2 activa-
tion of Akt (lane 4). These results indicate that TCR cross-
linking in activated T cells blocks IL-2 signal transduction
at a proximal step, and suppresses the activation of several
signaling pathways important for the proliferative response
to IL-2.
TCR ligation could block STAT5 activation by inhibit-
ing the expression or the function of components of the
IL-2R–Jak-STAT signaling pathway. Expression levels of
the IL-2R and the associated Jak1 and Jak3 kinases were
investigated (Fig. 4). Flow cytometry experiments demon-
strated that, as expected, TCR ligation resulted in decreased
cell surface expression of CD3 (Fig. 4 A), thus confirming
the efficacy of TCR engagement (39). In contrast, TCR
cross-linking did not have a significant effect on cell surface
expression of the IL-2R 
 
a 
 
(CD25), 
 
b 
 
(CD122), or 
 
g
 
c
 
 chains
(Fig. 4 A). TCR cross-linking also had no effect on cellular
levels of Jak1 or Jak3 (Fig. 4 B). The results demonstrating
no changes in IL-2R, Jak1, Jak3, and STAT5 levels after
TCR cross-linking indicate that cross-linking does not
modulate the expression of the components of the IL-2R–
Jak-STAT pathway that are required for STAT5 activation,
and suggest instead that TCR cross-linking modulates their
function.
 
Role of the MEK-ERK Signaling Pathway in Inhibition of
IL-2 Signaling.
 
We have previously demonstrated that
Figure 2. TCR ligation blocks
STAT5 tyrosine phosphoryla-
tion. After 1 h exposure to SEA
(2  mg/ml; A) or plate-bound
control or anti-CD3 antibodies
(B), T cells were stimulated for
10 min with IL-2 (100 U/ml)
and cell extracts were prepared.
Cell extracts were analyzed by
immunoblotting with antiphos-
photyrosine (P-tyr)–STAT5 antibodies (A), or STAT5 immunoprecipi-
tates were blotted with 4G10 antiphosphotyrosine antibodies (B). Filters
were stripped and reprobed with anti-STAT5 antibodies.
Figure 3. TCR ligation blocks activation of Jak1, Jak3, and Akt. Pre-
activated T cells were subjected to TCR ligation for 1 h, followed by a
10-min stimulation with IL-2 (100 U/ml). (A) Jak1 immunoprecipitates
(IP) were analyzed using immunoblotting (IB) with 4G10 (top panel),
and the same filter was reprobed with anti-Jak1 antibodies (second panel).
Alternatively, Jak1 immunoprecipitates were used in in vitro kinase assays
(75% of each immunoprecipitate, third panel) and analyzed using immu-
noblotting (25% of each immunoprecipitate, bottom panel). (B) Jak3 im-
munoprecipitates were obtained, 75% of each immunoprecipitate was
used in in vitro kinase assays (middle panel), and 25% of each immuno-
precipitate was analyzed using immunoblotting with 4G10 and Jak3 anti-
bodies (top and bottom panels). (C) Cell extracts were analyzed by im-
munoblotting with antibodies specific for serine 473–phosphorylated Akt
(upper panel) and against Akt (lower panel). 
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triggering of the kinase cascade leading to MEK and ERK
activation blocks IL-6 activation of Jaks upstream of STAT3
activation without altering expression of IL-6Rs or Jaks (28,
29), and others have shown that activation of the MEK-
ERK pathway can lead to suppression of proliferation (26,
27). Since cross-linking of the TCR activates a kinase cas-
cade involving PKC
 
®
 
Raf
 
®
 
MEK1, MEK2
 
®
 
ERK1, ERK2,
we investigated whether these kinases play a role in inhibi-
tion of IL-2 signaling (Fig. 5). The specific PKC inhibitor
GF109203X, but not the calcineurin inhibitor cyclosporin A,
reversed TCR inhibition of STAT5 activation (Fig. 5 A),
and inhibition was also reversed by the MEK inhibitor
PD98059 (Fig. 5 B). These results suggest that the PKC-
dependent activation of the MEK-ERK pathway plays an
important role in inhibition of IL-2 signaling. The role of
this pathway was further investigated using PMA, a direct
activator of PKC and a strong activator of downstream
MEKs and ERKs. Preincubation for 15 min with PMA re-
sulted in a strong suppression of STAT5 activation (Fig.
5 C), consistent with the rapid inhibition of IL-6 signaling
by this pathway (29). PMA treatment did not alter IL-2R
expression (data not shown), and cytokine signaling was
not globally inhibited by PMA, since IFN-
 
a
 
 signaling was
not inhibited in T cells (Fig. 5 C, lanes 5 and 6) or in my-
Figure 4. TCR ligation does not affect IL-2R, Jak1, or Jak3 expression.
Preactivated T cells were subjected to TCR ligation for 1 h and analyzed
by flow cytometry (A), or cell extracts were analyzed by immunoblotting
(IB; B).
Figure 5. TCR inhibition of IL-2 signaling is mediated by the MEK-
ERK signaling pathway. (A and B) Preactivated T cells were treated for
30 min with 1 mM GF109203X (GF), 0.5 mg/ml cyclosporin A (CsA), or
50 mM PD98059, followed by TCR ligation for 1 h and IL-2 (100 U/ml)
stimulation for 10 min. (C) Cells were treated with PMA (20 or 50 ng/ml)
for 15 min before a 10-min stimulation with IL-2 (100 U/ml) or IFN-g
(100 U/ml). (D) Kit225 cells were cotransfected in duplicate with 53
GRR GAS-luciferase, a b-galactosidase encoding plasmid, and either a
control empty vector, or, as indicated, the same vector containing a con-
stitutively active (CA) or kinase inactive (KI) MEK1 cDNA. Cells were
split and stimulated with IL-2 (100 U/ml) for 6 h. Luciferase activity was
normalized according to b-galactosidase activity, and a representative ex-
periment out of five performed is shown. 
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eloid cells (29). The role of MEKs and the functional signif-
icance of inhibition of IL-2 signaling mediated by these ki-
nases was investigated using transient transfections of the
IL-2–responsive Kit225 cell line and reporter gene assays
(Fig. 5 D). IL-2 treatment induced a sevenfold increase in
activity of the 53 GRR GAS-luciferase reporter gene,
which contains five copies of the GAS site from the FcgRI
promoter, and was previously shown to be induced in these
cells in an IL-2– and STAT5-dependent manner (32). This
induction was nearly completely blocked when cells were
cotransfected with a plasmid encoding constitutively active
MEK1, but not kinase-inactive MEK1 (Fig. 5 D). These re-
sults, taken together, indicate that activation of the PKC®
Raf®MEK®ERK pathway plays an important role in in-
hibition of IL-2 signaling by TCR ligation in activated T
cells, consistent with previously reported MEK-dependent
inhibition of proliferation in PC12 cells and primary fibro-
blasts (26, 27).
We have previously shown that rapid MEK-ERK–
dependent inhibition of IL-6 signaling occurs independently
of new protein or RNA synthesis (29), presumably through
phosphorylation of preexisting signaling components. Inhi-
bition of IL-2 signaling by PMA occurred within 15 min
(Fig. 5); inhibition by TCR ligation occurred reproducibly
within 30 min, and was less consistent with shorter incuba-
tion periods, possibly secondary to the time required for
cells to settle from suspension onto the bottom of anti-
body-coated wells (data not shown). The requirement for
new protein and RNA synthesis for inhibition of IL-2 sig-
naling by TCR ligation was investigated using cyclohexi-
mide and actinomycin D under conditions where these
agents effectively blocked new protein and RNA synthesis,
respectively (28, 29, 31; and data not shown). TCR liga-
tion blocked IL-2 activation of STAT5 in the presence of
cycloheximide and actinomycin D (Fig. 6), indicating that
inhibition can occur in the absence of new synthesis of
inhibitory molecules. These results do not exclude the pos-
sibility that TCR ligation may induce expression of inhibi-
tory molecules that contribute to inhibition of IL-2 signal-
ing, especially at later time points. SOCS1 and SOCS3 are
the two members of the SOCS family of proteins that are
currently known to inhibit Jak-STAT signal transduction,
and therefore the expression of these genes after TCR liga-
tion was examined (Fig. 7). Semiquantitative RT-PCR
that had been validated using Northern hybridization was
used as described previously (33). Positive control panels
show that Fos and IFN-g mRNA levels were dramatically
induced by TCR ligation with the expected kinetics (third
and fourth panels). SOCS3 mRNA was modestly and tran-
siently increased after TCR ligation (top panel), suggesting
that SOCS3 may contribute to inhibition of IL-2 signaling.
Activation of the MEK-ERK pathway by PMA did not in-
crease SOCS3 mRNA levels (top panel, lane 6), indicating
that inhibition of IL-2 signaling by the MEK-ERK path-
way is not mediated by SOCS3. SOCS1 mRNA levels
were regulated in a complex fashion by TCR ligation (sec-
ond panel); this result was obtained in multiple indepen-
dent experiments using three different sets of SOCS1 prim-
ers. Although we have not yet resolved whether the
regulation of SOCS1 may involve opposing effects on tran-
scription and RNA stability, it is clear that neither TCR li-
gation nor PMA treatment resulted in increased SOCS1
levels. Taken together, the results indicate that one rapid,
MEK-dependent component of inhibition of IL-2 signal-
ing is independent of the synthesis of new inhibitory pro-
teins, and suggest that inhibition of IL-2 signaling by the
MEK-ERK pathway is not dependent on induction of
SOCS1 or SOCS3 proteins. We have not excluded the
possibility that induction of inhibitory proteins, such as
SOCS3, may contribute to inhibition of IL-2 signaling,
possibly at later time points.
TCR Ligation Suppresses IL-2 Induction of Genes and Cell
Cycle Regulators, and IL-2–dependent Cell Expansion. The
functional consequences of TCR-induced inhibition of IL-2
signaling were investigated by analyzing expression of CIS,
PGE2R, and CCR2, which are induced by IL-2, but not
by the TCR (34, 42, 43). Ligation of the TCR before
addition of IL-2 effectively blocked the induction of CIS
and PGE2R mRNA (Fig. 8 A), and suppressed expression
of CIS and PGE2R genes even when cells were exposed
to high doses of IL-2 before TCR ligation (Fig. 8 B). PMA
plus ionomycin more strongly inhibited expression of IL-2–
dependent genes (Fig. 8 B), which correlated with stronger
inhibition of STAT5 (data not shown). CIS transcription is
STAT5 dependent (43), and the CIS and PGE2R genes are
regulated by IL-2 at the transcriptional level, indicating that
Figure 6. Inhibition of IL-2 signaling after TCR ligation does not re-
quire new RNA or protein synthesis. Preactivated T cells were preincu-
bated for 30 min with cycloheximide (CHX, 40 mg/ml) or actinomycin
D (Act D, 5 mg/ml), then subjected to TCR ligation for 1 h followed by
10 min of stimulation with IL-2.
Figure 7. Regulation of SOCS mRNA levels after TCR ligation. Pre-
activated T cells were added to wells containing anti-CD3 antibodies, and
cells were harvested at the indicated time points. mRNA levels were de-
termined using semiquantitative RT-PCR, as described previously (refer-
ence 33).1269 Lee et al.
TCR ligation likely inhibited gene expression by blocking
IL-2–induced transcription. TCR-mediated suppression of
IL-2 induction of CCR2 (42) was confirmed in our system
using flow cytometry (Fig. 8 C). These results, together with
the suppression of IL-2 activation of reporter gene activity
(Fig. 5 D), demonstrate that inhibition of IL-2 signaling by
TCR ligation in activated T cells has important functional
consequences for modulation of gene expression.
Important events for IL-2–induced progression into S
phase of the cell cycle include upregulation of cyclin D3 and
cdk2 levels (32, 44, 45), leading to increased cdk activity
and phosphorylation of Rb. TCR ligation in rapidly prolif-
erating, IL-2–dependent T cells resulted in downregulation
of cyclin D3 and cdk2 levels (Fig. 9). Downregulation of
cyclin D3 and cdk2 levels would be predicted to result in
increased levels of underphosphorylated Rb, and suppres-
sion of proliferation. As predicted, TCR cross-linking re-
sulted in increased levels of underphosphorylated Rb (Fig. 9).
The effects of PMA or PMA plus ionomycin were compa-
rable to, or greater than, the effects of TCR ligation (Fig. 9),
and PMA plus ionomycin increased underphosphorylated
Rb levels more dramatically in other experiments (data not
shown). These results show that TCR ligation, or pharma-
cologic mimicking of TCR ligation, blocks IL-2 signals that
are important for cell cycle progression.
Proliferation of activated T cells in these cultures was
highly dependent on exogenous IL-2 (data not shown),
consistent with previous reports (22). TCR ligation in rap-
idly proliferating, IL-2–dependent T cells led to a 65% de-
crease in T cell proliferation as assessed by [3H]thymidine
incorporation (Fig. 10 A; a representative experiment out
of four performed is shown). Cell counts performed on
parallel wells at the same time point (after 4 h of TCR liga-
tion) demonstrated comparable numbers of viable cells (data
not shown), indicating that decreased [3H]thymidine incor-
poration reflected inhibition of proliferation rather than cell
death. PMA inhibited proliferation comparably to TCR
cross-linking, and PMA plus ionomycin was more effective
(Fig. 10 A). The effect of TCR ligation on T cell expansion
was determined. 24 h after plating of proliferating IL-2–
dependent T cells, control cultures demonstrated a 90% in-
crease in the number of viable cells, whereas cultures sub-
jected to TCR ligation demonstrated only a 10% increase
in viable cells (Fig. 10 B; a representative experiment out of
five performed is shown). The decreased cell numbers in
TCR-stimulated cultures were primarily secondary to sup-
pression of growth, although a small increase in cell death
was detected 24 h after TCR ligation (Fig. 10 B). Direct
cross-linking of Fas receptors using agonist antibodies at
this early point in culture (after 2 d of culture in exogenous
high dose IL-2) had minimal effect on cell numbers, indi-
cating that the decrease in T cell numbers detected (Fig. 10 B)
was not secondary to a Fas-mediated mechanism. As pre-
dicted, TCR signaling affected the distribution of T cells in
different phases of the cell cycle, and Fig. 8 C shows a de-
crease in actively cycling T cells in S and G2/M phases of
the cell cycle after SEA treatment. SEA treatment induced
an increase in apoptosis, as assessed by numbers of cells
containing subdiploid levels of DNA, from 4 to 12% of
cells (Fig. 10 C), and the possible role of a Fas-mediated
Figure 8. TCR inhibition of IL-2–induced gene expression. (A) Pre-
activated T cells were subjected to TCR ligation for 1 h followed by 1 h
of stimulation with IL-2, and mRNA levels were determined using semi-
quantitative RT-PCR, as described previously (reference 33). (B) T cells
activated with OKT3 for 3 d were cultured for an additional 2 d in IL-2
(100 U/ml), and then added to wells containing control or anti-CD3 an-
tibodies for 5 h. resting, cells not exposed to IL-2. P/iono, PMA and ion-
omycin. (C) Cell surface CCR2 expression after 24 h of TCR ligation
was determined using flow cytometry. iso, isotype control.
Figure 9. TCR regulation of
cell cycle regulatory proteins. T
cells activated with OKT3 for 3 d
were cultured for an additional 2 d
in IL-2 (100 U/ml), and then
added to wells containing con-
trol or anti-CD3 antibodies. Cell
extracts were prepared after 5 h
of TCR ligation or PMA and
ionomycin (P/iono) treatment,
and analyzed using immunoblot-
ting. The same filter was sequen-
tially probed with the indicated
antibodies. under-P-Rb, under-
phosphorylated Rb.1270 TCR-mediated Inhibition of IL-2 Signaling
mechanism in apoptosis has not yet been investigated. TCR
ligation resulted in decreased cell numbers throughout the
subsequent 5 d of culture, with a resulting fourfold lower
yield of viable cells in TCR-stimulated as opposed to con-
trol cultures (Fig. 10 D; a representative experiment out of
three performed is shown). The effect of PMA was compa-
rable to, and the effect of PMA plus ionomycin greater
than, the effect of TCR ligation (Fig. 10 D). Increased cell
death contributed more to the lower cell recovery 5 d after
TCR cross-linking (Fig. 10 E) than 1 d after TCR ligation
(Fig. 10 B). Cells became sensitive to apoptosis triggered by
cross-linking cell surface Fas receptors during the final 2–3 d
of these cultures (data not shown), and the relative contri-
butions of cytokine withdrawal and Fas-dependent mecha-
nisms to this increased cell death have not yet been resolved.
These results demonstrate that TCR-induced inhibition of
IL-2 signaling leads to growth arrest, and suggest that inhi-
bition is linked to subsequent cell death.
Discussion
In T cell activation, initial encounter with antigen and
TCR ligation induces quiescent cells to enter the G1 phase
of the cell cycle and to express cytokine receptors, and ren-
ders them competent to progress through the cell cycle in
response to cytokines and growth factors such as IL-2 (22).
In this initial phase, the cells are not cytokine dependent,
and MEK-ERK signaling downstream of TCR ligation plays
a role in activation and priming for expansion (25). Upon
subsequent exposure to cytokines, T cells enter a prolifera-
tive phase during which they are cytokine dependent for
growth and survival (22). At this point, persistence of anti-
gen leads to negative feedback and limitation of clonal
expansion. The best-characterized mechanism of negative
feedback is TCR-triggered apoptosis mediated by death re-
ceptors such as Fas and TNF receptor 1 (14), and defects in
apoptosis have been implicated in autoimmunity in mice
and human patients (14, 46–48). The results described
herein identify TCR-induced, rapidly acting, and MEK-
dependent inhibition of IL-2 signaling as a novel physio-
logical mechanism that underlies growth arrest of primary
proliferating T cells. Given the recent evidence that TCR-
induced apoptosis is dependent on prior growth arrest (15),
it is possible that TCR-induced blockade of IL-2 signaling
and subsequent growth arrest may represent an important
first step that, along with additional factors, makes cells sus-
ceptible to undergo apoptosis at a later time point. Apopto-
sis may be secondary to decreased survival signals or may
occur by a Fas-dependent mechanism, and the relationship
between inhibition of IL-2 signaling and apoptosis will be
further investigated in future work. Growth arrest was ob-
served before the onset of significant levels of apoptosis
(Fig. 10), and may correspond to an additional level of lim-
iting T cell responses that functions in addition to apop-
tosis. This growth arrest may contribute to the limitation in
T cell expansion in the absence of cell death that has been
Figure 10. Inhibition of IL-2–dependent T cell expansion by TCR ligation. T cells activated with OKT3 or SEA for 3 d and cultured in IL-2 for 2 d
to obtain rapidly proliferating cells were used. (A) [3H]Thymidine incorporation. [3H]Thymidine was added to triplicate wells 2 h after cells were plated,
and cells were harvested and [3H]thymidine incorporation measured after an additional 4 h. A representative experiment out of four performed is shown.
(B) Cell counts from duplicate wells were obtained 24 h after cells were plated. Cell viability was determined using trypan blue and propidium iodide ex-
clusion. A representative experiment out of five performed is shown. (C) Cell cycle analysis was performed on T cells 24 h after addition of APCs and
SEA, as described previously (reference 33). (D and E) Cell counts were obtained 3 and 5 d after cells were plated. D shows viable cell numbers, and E
shows relative proportions of live and dead cells on the fifth day of culture. A representative experiment out of three performed is shown.1271 Lee et al.
described under certain circumstances, such as high dose
paralysis occurring in the presence of high doses of antigens,
and in persistent infections (2, 9, 11, 12, 23). IL-2–depen-
dent T cell expansion was limited but not blocked, suggest-
ing that this mechanism does not completely prevent the
normal progression of an immune response, but that inter-
play between TCR and cytokine signals of varying intensi-
ties and at different time points in T cell activation deter-
mines the magnitude of the response.
At first glance, inhibition of IL-2 signaling and prolifera-
tion by an MEK-dependent mechanism may appear para-
doxical, since activation of the MEK-ERK pathway by the
TCR in resting T cells primes the cells for proliferation
(22, 25, 49), and activation of the MEK-ERK pathway by
Ras has been linked to proliferation in transformed cells
(50). However, it is becoming increasingly clear that the
effects of MEK-ERK signaling on cell growth depend on
the physiological state of the cell, and either proliferation or
growth arrest and senescence may occur (25–27). During
activation, T cells progress from a quiescent, cytokine-
independent state to a proliferative state where growth and
survival are exquisitely cytokine dependent. It is only dur-
ing this cytokine-dependent state that the antiproliferative
aspects of TCR-triggered MEK-ERK signaling become ap-
parent, through inhibition of cytokine signal transduction.
TCR ligation and MEK-ERK signaling blocked IL-2
induction of STAT5, activation of a STAT5-dependent re-
porter gene (Fig. 5), and activation of expression of the
IL-2–inducible CIS, PGE2R, and CCR2 genes (Fig. 8). The
CIS gene is activated primarily by STAT5 (43), and thus
TCR-mediated inhibition of CIS expression provides a
functional correlate to inhibition of STAT5 activation. It is
not yet clear if inhibition of PGE2R and CCR2 expression
is secondary to blocking STAT5 or other IL-2 signaling
pathways, but inhibition of these genes clearly demon-
strates that TCR inhibition of IL-2 signaling has important
functional consequences for T cell phenotype. Inhibition of
IL-2 signaling also resulted in inhibition of IL-2–dependent
proliferation. Suppression of proliferation may be medi-
ated, at least in part, through inhibition of STAT5, which
has been shown to play an important role in proliferation
of primary T cells (51–53). Another important mechanism
by which IL-2 stimulates T cell proliferation is through in-
duction of cdk2 (54) and cyclin D3 expression (32, 45),
with concomitant phosphorylation of Rb and progression
from G1 into S phase of the cell cycle. IL-2 regulation of
cyclin D3 and Rb has been shown to be mediated by Akt
(32), and activation of Akt was blocked by TCR cross-
linking (Fig. 3). As predicted, this resulted in decreased lev-
els of IL-2–induced cyclin D3 and cdk2 expression, and
decreased phosphorylation of Rb (Fig. 9). Thus, our results
demonstrate that TCR ligation blocked IL-2–dependent
proliferation of T cells by blocking at least two signaling
pathways important for proliferation.
A recent report by Welte et al. (40) described rapid acti-
vation of STAT5 tyrosine phosphorylation that was de-
tected 7 min after TCR ligation in the murine D10 Th2
clone, and was very transient, such that tyrosine phosphor-
ylation was not detected 15 min after TCR ligation. TCR
activation of STAT5 tyrosine phosphorylation was signifi-
cantly weaker than activation by IL-2, and activation of
STAT5 DNA binding after TCR ligation was detected
only in transfected 293 cells that overexpressed the relevant
signaling components (40). In our system, STAT5 activity
was examined 0.5–4 h after TCR ligation, and thus we
would not have detected very rapid and transient activation
of STAT5. Our results are consistent with a previous report
that TCR ligation did not induce STAT5 activation (55).
Welte et al. suggested that TCR-mediated STAT5 activa-
tion played a role in TCR-induced proliferation based on
results obtained using overexpression of a dominant nega-
tive STAT5-Y694F, which contains a mutation in the
STAT5 tyrosine residue that becomes phosphorylated. In
contrast to Welte et al. (40), we show that TCR ligation
blocks subsequent activation of STAT5 by IL-2, and blocks
IL-2–dependent proliferation (Fig. 10). The most likely ex-
planation for these different findings is that they represent
differences between quiescent T cells, where TCR ligation
induces proliferation (40), and actively cycling T cells, where
TCR ligation induces growth arrest (Fig. 10). Alterna-
tively, although D10 cells do not produce IL-2, they pro-
duce proliferative cytokines such as IL-4, and high levels of
overexpressed STAT5-Y694 may have resulted in loss of
specificity in receptor docking and blocked proliferation
(40) by blocking STAT signaling by cytokines such as IL-4.
Inhibition of cytokine signaling is a rapidly emerging
area, and several constitutive mechanisms of downmodulat-
ing STAT activity have been described, including dephos-
phorylation, proteolytic degradation, or association with in-
hibitory molecules (56–61). We have previously described
a rapidly inducible mechanism of inhibition of IL-6 signal-
ing (28, 29). Similarities between the mechanisms of inhi-
bition of IL-6 signaling in myeloid cells and of IL-2 signal-
ing in T cells include rapid induction within 15–60 min of
addition of inhibitory factors, independence of new protein
or RNA synthesis (at early time points), blockade of signal-
ing at a proximal step in signal transduction without any
changes in expression of receptors, Jaks, or STATs, and de-
pendence on the MEK-ERK kinase cascade. These results
suggest that inhibition of IL-2 and IL-6 signaling is achieved
through MEK-dependent modification of IL-2 and IL-6
signaling components. Another previously described induc-
ible mechanism for inhibiting the Jak-STAT pathway is cyto-
kine-mediated induction of expression of SOCS/Jak bind-
ing (JAB)/STAT-inducible STAT inhibitor (SSI) proteins,
which interact with and inhibit Jaks (62–64). Induction of
SOCS3 may contribute to the inhibition of IL-2 signaling
(Fig. 7), and inhibition of IL-6 signaling by GM-CSF at
later time points also depended on new protein synthesis,
likely of SOCS proteins (28). Thus, two distinct inhibitory
mechanisms, mediated by MAPKs and SOCS proteins,
may function in tandem to achieve effective inhibition of sig-
naling at both early and later time points after addition of an
inhibitory factor. Inhibition of IL-2 and IL-6 signaling in T
cells, myeloid cells, and several cell lines by the MEK-ERK
pathway indicates that this inhibitory mechanism functions1272 TCR-mediated Inhibition of IL-2 Signaling
in a number of cell types and physiological settings. Inter-
estingly, additional important immune receptors that acti-
vate the MEK-ERK pathway, FcRs and CR3, have also
been shown to inhibit cytokine and Jak-STAT signaling,
although the mechanisms of inhibition and the role of the
MEK-ERK pathway were not resolved (65, 66). Thus, since
the major receptors that mediate interactions of immune
cells with antigenic stimuli, antigen, Fc, and complement
receptors, activate the MEK-ERK pathway, cross-talk be-
tween the MEK-ERK and Jak-STAT pathways may play a
particularly important role in modulation of cytokine sig-
naling in immune cells.
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